American multinational pharma, maker of GLP-1 therapies; pivotal in weight-loss and diabetes drugs.
New observational data suggests Shingrix vaccination in older adults is associated with lower cardiovascular risk and reduced dementia incidence over multi-year follow-ups. Studies compare Shingrix to Zostavax and find reductions in heart disease, stroke, and dementia, with stronger signals in men for heart outcomes.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
A wave of AI-related IPOs from SpaceX, Anthropic and OpenAI is unfolding, with markets facing a flood of new stock. Retail demand remains strong for SpaceX, but analysts warn supply could overwhelm demand, pressuring prices and testing market resilience.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
Three articles report on cutting-edge biotech and AI-driven medicine: base editing in embryos stirs debate over cures and designer babies; Google-backed AI seeks clinical trust; Life Biosciences tests cellular reprogramming in humans to combat aging and glaucoma.
Markets are stabilising after a stretch of high activity in tech options, with traders shifting focus as implied volatility cools. Small caps are leading potential next moves, while global equities reflect a policy-led, carry-friendly regime.
Pennsylvania has rolled out stricter guardrails for data center projects, including energy cost commitments, community engagement, and environmental protections. The move aims to accelerate development while addressing local concerns. Projects like Boson and The Highland are cited as tests of the new framework amid bipartisan push for faster permitting.
POLITICO, Independent, Business Insider UK and others report on RAISE US, a bipartisan nonprofit led by Gina Raimondo and Eric Holcomb. The group mobilizes $500m+ from tech firms to fund workforce programs, pilots in Arkansas, Maryland, Utah and Connecticut, and policy work to shield workers from AI disruption.
The UK–US pharmaceutical deal has led to a BMJ analysis predicting the NHS will divert billions to fund new medicines, risking hundreds of thousands of excess deaths by 2036, with the toll higher if social care funding is included.
The 340B program, which lets hospitals buy discounted outpatient drugs for low-income patients, is facing a new CMS rule changing reimbursement formulas to reduce payments by about 40%. The move aims to lower patient costs but could shrink hospital revenues and affect services and jobs. The rule follows an executive order in 2025 and reflects ongoing political battles between hospitals and the pharmaceutical industry.
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
Barron’s reports Lilly’s plan to seek approval for its newest weight‑loss drug in 2027, signaling a potential pipeline expansion. The move follows a mixed earnings season for Danaher, with investors weighing the timing and impact on long‑term growth.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Lilly and Novo Nordisk have surpassed forecasts in Q2, widening the gap in the obesity-drug space. Lilly leads in the US with about 61% share; Novo raises full-year outlook but faces questions about Wegovy's growth and its pipeline. Investors are watching whether Novo can sustain momentum as competition intensifies.
CVS Health has raised its 2026 guidance, citing stronger profits from its insurance and retail pharmacy segments and a marked improvement in its Aetna unit. The company is expanding GLP-1 weight-loss access through MinuteClinic, while flagging higher medical costs and macro risks.
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.
Lilly has filed six lawsuits targeting online sellers and clinics marketing retatrutide, a GLP-1 drug still in Phase 3 trials for obesity and diabetes, while US authorities report a surge in illicit shipments. The company says products sold online are unverified and unapproved, and warns of substantial health risks.
Norway’s sovereign wealth fund has posted a record first-half profit of about $185 billion as markets rally in tech names. It has disclosed a 0.05% stake in SpaceX, valuing the position at just over $1.2 billion, while its larger holdings include Nvidia, Apple and Microsoft. NBIM says the fund remains globally diversified and long-term oriented.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.